|
US5116742A
(en)
|
1986-12-03 |
1992-05-26 |
University Patents, Inc. |
RNA ribozyme restriction endoribonucleases and methods
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
WO1991003553A1
(en)
|
1989-09-05 |
1991-03-21 |
Immunex Corporation |
TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
|
|
TW221049B
(enExample)
|
1991-12-20 |
1994-02-11 |
Lilly Co Eli |
|
|
US5705398A
(en)
|
1994-03-02 |
1998-01-06 |
The Scripps Research Institute |
Methods for identifying inhibitors of LPS-mediated LBP binding
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
MX336813B
(es)
|
1996-02-09 |
2016-02-02 |
Abbvie Biotechnology Ltd |
Anticuerpos humanos que ligan el tnfa humano.
|
|
HRP20000724A2
(en)
*
|
1998-05-05 |
2001-06-30 |
Hoffmann La Roche |
Pyrazole derivatives as p-38 map kinase inhibitors
|
|
PL2298743T3
(pl)
*
|
2003-06-26 |
2013-02-28 |
Novartis Ag |
Inhibitory kinaz P38 na bazie 5-członowych heterocykli
|
|
US20080280910A1
(en)
*
|
2007-03-22 |
2008-11-13 |
Keith Allan Menear |
Phthalazinone derivatives
|
|
US8884006B2
(en)
|
2011-09-19 |
2014-11-11 |
University Of Puerto Rico |
Small-molecule inhibitors of Rac1 in metastatic breast cancer
|
|
US9701689B2
(en)
|
2012-11-30 |
2017-07-11 |
Kyowa Hakko Kirin Co., Ltd. |
Substituted pyridines and pyridazines as CCR10 receptor inhibitors
|
|
ITMI20131658A1
(it)
|
2013-10-08 |
2015-04-09 |
Getters Spa |
Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
|
|
US9714288B2
(en)
|
2014-09-30 |
2017-07-25 |
The Regents Of The University Of California |
Antisense compounds and uses thereof
|
|
KR102727059B1
(ko)
*
|
2015-02-16 |
2024-11-05 |
더 유니버서티 어브 퀸슬랜드 |
설포닐우레아와 관련 화합물 및 그 용도
|
|
EP3368036B1
(en)
*
|
2015-10-29 |
2022-07-20 |
Merck Sharp & Dohme LLC |
Macrocyclic pyridine-n-oxide derivatives as factor xia inhibitors
|
|
FR3046933B1
(fr)
*
|
2016-01-25 |
2018-03-02 |
Galderma Research & Development |
Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
|
|
ES2940611T3
(es)
*
|
2016-04-18 |
2023-05-09 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
US11597706B2
(en)
*
|
2016-04-18 |
2023-03-07 |
Novartis Ag |
Compounds and compositions for treating conditions associated with NLRP activity
|
|
KR20180134395A
(ko)
|
2016-04-19 |
2018-12-18 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
|
ES2844184T3
(es)
*
|
2016-06-14 |
2021-07-21 |
Bristol Myers Squibb Co |
4-hidroxi-3-sulfonilpiridin-2(1H)-onas como agonistas del receptor de APJ
|
|
CA3047336A1
(en)
|
2017-01-23 |
2018-07-26 |
Jecure Therapeutics, Inc. |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
EP3634951B8
(en)
|
2017-06-09 |
2024-08-21 |
Zydus Lifesciences Limited |
Novel substituted sulfoximine compounds
|
|
RS65492B1
(sr)
|
2017-07-24 |
2024-05-31 |
Novartis Ag |
Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
|
|
US11518739B2
(en)
|
2017-08-15 |
2022-12-06 |
Inflazome Limited |
Sulfonamide carboxamide compounds
|
|
EP3823974A1
(en)
|
2018-07-20 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Sulfonimidamide compounds as inhibitors of interleukin-1 activity
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
BR112021003665A2
(pt)
|
2018-09-13 |
2021-05-18 |
Bayer Aktiengesellschaft |
derivados de heterocicleno como agentes de controle de pragas
|
|
AU2020208644A1
(en)
|
2019-01-18 |
2021-08-26 |
Nuvation Bio Inc. |
Heterocyclic compounds as adenosine antagonists
|
|
US20220378801A1
(en)
|
2019-06-21 |
2022-12-01 |
Ac Immune Sa |
Novel compounds
|